Notably, the experimental suppression of FMO3 in insulin-resistant mice effectively inhibited FoxO1, a key metabolic regulatory node, and completely circumvented the progression of hyperglycemia, hyperlipidemia, and atherosclerosis (54). Here, FMO3 is linked to hyperlipidemia.